Your browser is no longer supported. Please, upgrade your browser.
Amneal Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.13 Insider Own0.50% Shs Outstand147.64M Perf Week-5.63%
Market Cap1.74B Forward P/E5.96 EPS next Y0.87 Insider Trans-4.49% Shs Float116.74M Perf Month-15.03%
Income-18.90M PEG- EPS next Q0.19 Inst Own60.60% Short Float3.50% Perf Quarter0.00%
Sales1.99B P/S0.87 EPS this Y95.40% Inst Trans-5.25% Short Ratio2.02 Perf Half Y8.33%
Book/sh2.05 P/B2.54 EPS next Y11.79% ROA1.50% Target Price6.45 Perf Year46.48%
Cash/sh1.02 P/C5.09 EPS next 5Y-12.10% ROE20.20% 52W Range3.44 - 7.45 Perf YTD13.79%
Dividend- P/FCF8.14 EPS past 5Y-17.50% ROI2.70% 52W High-30.15% Beta1.26
Dividend %- Quick Ratio1.60 Sales past 5Y18.30% Gross Margin33.30% 52W Low51.20% ATR0.29
Employees5500 Current Ratio2.30 Sales Q/Q28.40% Oper. Margin2.40% RSI (14)35.28 Volatility6.46% 4.45%
OptionableYes Debt/Eq9.50 EPS Q/Q90.90% Profit Margin3.10% Rel Volume1.18 Prev Close5.78
ShortableYes LT Debt/Eq9.34 EarningsMay 07 BMO Payout0.00% Avg Volume2.03M Price5.20
Recom2.40 SMA20-9.65% SMA50-13.68% SMA2006.41% Volume2,385,410 Change-10.03%
Apr-07-21Resumed RBC Capital Mkts Sector Perform $5
Mar-08-21Upgrade Goldman Sell → Buy $4 → $6.50
Dec-14-20Upgrade Guggenheim Neutral → Buy $5.50
Dec-14-20Upgrade Barclays Equal Weight → Overweight $4.50 → $6
Jul-27-20Initiated Goldman Sell $4
May-12-20Upgrade Guggenheim Sell → Neutral
Dec-12-19Downgrade Raymond James Outperform → Mkt Perform
Nov-12-19Downgrade JP Morgan Neutral → Underweight
Nov-07-19Downgrade SVB Leerink Outperform → Mkt Perform
Jul-22-19Upgrade SVB Leerink Mkt Perform → Outperform $11 → $5
Jul-11-19Downgrade RBC Capital Mkts Outperform → Sector Perform $11 → $6
Jul-08-19Upgrade Piper Jaffray Neutral → Overweight
Jun-11-19Initiated Barclays Equal Weight $9
May-21-19Upgrade Raymond James Mkt Perform → Strong Buy $13
Mar-20-19Initiated SunTrust Buy $16
Mar-08-19Downgrade SVB Leerink Outperform → Mkt Perform $16 → $12
Dec-14-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-16-18Downgrade SunTrust Buy → Hold
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Jul-23-18Initiated Morgan Stanley Overweight $22
May-07-21 06:00PM  
Apr-30-21 03:00PM  
Apr-15-21 08:00AM  
Apr-12-21 08:15AM  
Apr-09-21 01:32AM  
Apr-05-21 08:00AM  
Mar-31-21 11:50AM  
Mar-15-21 04:08PM  
Mar-08-21 09:51AM  
Mar-01-21 10:39AM  
Feb-26-21 06:30PM  
Feb-25-21 10:04AM  
Feb-22-21 04:05PM  
Feb-10-21 11:40AM  
Feb-09-21 12:10PM  
Feb-07-21 11:32PM  
Feb-04-21 08:00AM  
Jan-15-21 11:40AM  
Jan-12-21 06:00AM  
Jan-08-21 08:00AM  
Jan-05-21 09:23AM  
Dec-16-20 01:57PM  
Dec-11-20 10:00PM  
Nov-23-20 10:24AM  
Nov-16-20 09:45AM  
Nov-11-20 08:35AM  
Nov-10-20 05:09AM  
Nov-06-20 09:30PM  
Nov-05-20 10:08AM  
Oct-30-20 12:30PM  
Oct-29-20 05:50PM  
Oct-22-20 12:10PM  
Oct-21-20 10:46AM  
Oct-20-20 11:30AM  
Oct-15-20 10:26AM  
Oct-14-20 06:15AM  
Oct-08-20 03:10PM  
Sep-01-20 08:00AM  
Aug-25-20 09:00AM  
Aug-06-20 08:35AM  
Aug-03-20 12:08PM  
Jul-31-20 05:45PM  
Jul-30-20 12:33PM  
Jul-23-20 05:45PM  
Jul-22-20 12:10PM  
Jul-17-20 05:45PM  
Jul-16-20 07:29AM  
Jul-13-20 09:44AM  
Jul-10-20 08:00AM  
Jul-09-20 07:18AM  
Jul-08-20 05:50PM  
Jul-07-20 11:40AM  
Jun-30-20 10:21AM  
Jun-26-20 10:48AM  
Jun-19-20 11:40AM  
Jun-16-20 08:33AM  
Jun-14-20 09:33PM  
Jun-12-20 08:49AM  
Jun-09-20 08:47AM  
Jun-08-20 07:22AM  
Jun-03-20 11:40AM  
May-26-20 07:49AM  
May-18-20 11:40AM  
May-17-20 10:27AM  
May-15-20 12:00PM  
May-12-20 10:09AM  
May-11-20 08:00PM  
May-08-20 08:53AM  
May-06-20 06:49PM  
Apr-24-20 04:05PM  
Apr-16-20 07:00AM  
Apr-15-20 04:30PM  
Apr-10-20 11:18AM  
Apr-07-20 09:46AM  
Mar-26-20 04:30PM  
Mar-25-20 08:16AM  
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah NikitaExecutive Vice PresidentMar 15Option Exercise2.7536,33099,908248,251Mar 17 04:04 PM
Todisco JosephExecutive Vice PresidentMar 15Option Exercise2.7536,33099,908316,270Mar 17 04:05 PM
Shah NikitaExecutive Vice PresidentMar 15Sale6.8736,330249,489211,921Mar 17 04:04 PM
Todisco JosephExecutive Vice PresidentMar 15Sale6.8236,330247,865279,940Mar 17 04:05 PM
Kiely JohnDirectorMay 19Buy4.4010,00044,00010,000May 19 11:46 AM
George Jeffrey P.DirectorMay 15Buy4.1623,81099,05023,810May 15 04:15 PM